title: Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
abstract: The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 99mTc-P829, compared with that of 111In-pentetreotide.
  
  
  METHODS
  Forty-three patients (32 men, 11 women; age range, 24-78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 patients with carcinoid tumors, and 16 patients with other types of functioning (n = 6) or nonfunctioning (n = 10) endocrine tumors. 111In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 microg somatostatin analog labeled with 148 +/- 17 MBq 111In, and SPECT was performed 24 h after injection. Similar (99m)Tc-P829 planar images were obtained at 1, 4-6, and 24 h after injection of 50 microg peptide labeled with 991.6 +/- 187.59 MBq 99mTc. Abdominal SPECT was performed 4-6 h after injection.
  
  
  RESULTS
  111In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas 99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P < 0.005). In the liver, 129 sites (in 24 patients) were detected by 111In-pentetreotide scintigraphy and 34 sites (in 10 patients) were detected by 99mTc-P829 scintigraphy.
  
  
  CONCLUSIONS
  In patients with endocrine tumors, the detection rate of 99mTc-P829 scintigraphy was lower than that of 111In-pentetreotide scintigraphy, which appeared to be more sensitive, especially for liver metastases.
authors.affiliation: Nuclear Medicine Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France. rachida.lebtahi@bch.ap-hop-paris.fr
authors.forename: Rachida
authors.initials: R
authors.lastname: Lebtahi
authors.forename: Joseph
authors.initials: J
authors.lastname: Le Cloirec
authors.forename: Claire
authors.initials: C
authors.lastname: Houzard
authors.forename: Doumit
authors.initials: D
authors.lastname: Daou
authors.forename: Iradj
authors.initials: I
authors.lastname: Sobhani
authors.forename: Geneviève
authors.initials: G
authors.lastname: Sassolas
authors.forename: Michel
authors.initials: M
authors.lastname: Mignon
authors.forename: Patrick
authors.initials: P
authors.lastname: Bourguet
authors.forename: Dominique
authors.initials: D
authors.lastname: Le Guludec
mesh_terms: D002276:Carcinoid Tumor / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D015609:Organotechnetium Compounds; D010456:Peptides, Cyclic; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D013004:Somatostatin / Q000031:analogs & derivatives; D015899:Tomography, Emission-Computed, Single-Photon; D015043:Zollinger-Ellison Syndrome / Q000000981:diagnostic imaging
chemical_list: D007205:Indium Radioisotopes; D015609:Organotechnetium Compounds; D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; D013004:Somatostatin; C081788:pentetreotide; C100464:P 829